The National Comprehensive Cancer Network now recommends molecular profiling for all patients eligible for therapy, regardless of disease stage.
The National Comprehensive Cancer Network (NCCN) has updated its clinical guidelines to call for comprehensive molecular profiling for all patients with pancreatic cancer who are eligible for anti-cancer therapy. This update marks a shift in how the disease is evaluated by requiring testing across all stages, rather than prioritizing testing only for advanced or metastatic cases.
The revised NCCN guidelines recommend tumor molecular profiling, including next-generation sequencing (NGS) and RNA sequencing, for all therapy candidates. By identifying actionable genetic alterations, such as mutations, gene fusions, and biomarkers including microsatellite instability, clinicians can better match patients to targeted therapies and clinical trials.
“Pancreatic cancer has historically been treated as a single disease, but we now know it is biologically diverse,” says Diane Simeone, MD, director of UC San Diego Moores Cancer Center and founder and chief scientific advisor of PRECEDE, in a release. “These updated guidelines reflect where the science is today, and treatment decisions should be informed by the unique molecular profile of each patient’s tumor.”
The guidelines also emphasize the use of both DNA- and RNA-based testing approaches. Additionally, the update notes the potential role of circulating tumor DNA for diagnostics when tissue samples are not available.
For PRECEDE, a global collaborative of more than 65 institutions, the NCCN update highlights a move toward earlier, individualized intervention.
“This is a pivotal moment for pancreatic cancer care,” says Simeone in a release. “As molecular testing moves earlier in the treatment pathway, we have an opportunity to intervene more effectively and connect patients with therapies that are tailored to their disease biology.”
While the guidelines reflect recent advances in oncology, PRECEDE leaders note that policy and coverage frameworks have not kept pace. Current Medicare coverage for NGS remains largely aligned with older, stage-based models of care, which may limit testing access for some patients.
“Scientific progress is moving quickly, and clinical guidelines are evolving accordingly,” says Simeone in a release. “Ensuring that coverage policies keep pace will be critical to making these advances accessible to all patients who can benefit.”
Pancreatic cancer remains a significant clinical challenge, with a five-year survival rate of approximately 13%. The NCCN’s updated recommendations are intended to ensure more patients receive treatment informed by the specific biological characteristics of their disease.
ID 203642505 © Putilich | Dreamstime.com
